HIGHFDA DRUG

Granules Pharmaceuticals Amphetamine Salts Recall Over Impurities Degradation Specifications (2025)

Granules Pharmaceuticals recalled 11,895 bottles of an extended-release amphetamine product due to failed impurities and degradation specifications. The recall is active nationwide in the United States. The FDA notice lists a high hazard level and urges stop-use and contact with the company or a healthcare provider.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
August 28, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
August 28, 2025
Hazard Level
HIGH
Brands
Dextroamphetamine Saccharate, Granules Pharmaceuticals Inc.
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, PREGNANT

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Dextroamphetamine Saccharate, Granules Pharmaceuticals Inc.
Product type
Extended-Release Capsules (Mixed Salts of a Single Entity Amphetamine Product)
Model numbers
lot#: GPC250159A, Exp Date: 06-22-2027
UPC codes
70010-029, 70010-030, 70010-031, 70010-032, 70010-033, 70010-034, 70010-029-01, 70010-030-01 +4 more
Sizes
10 mg, 100 capsules
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    August 28, 2025

  2. Reported by FDA DRUG

    October 1, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Impurities/Degradation Specifications:

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Granules Pharmaceuticals Inc. or your healthcare provider for guidance. Notification method: E-Mail

About This Product

This is a prescription extended-release amphetamine product used for ADHD and narcolepsy in adults and certain patients. It is manufactured by a US facility.

Why This Is Dangerous

The defect relates to impurities/degradation specifications which could affect safety, but specific health effects are not detailed in the release.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

No injuries reported yet; immediate stop-use is required to prevent potential risk and ensure patient safety.

Practical Guidance

How to identify if yours is affected

  1. Look for NDC 70010-030-01 on the bottle
  2. Check lot: GPC250159A
  3. Verify Exp Date: 06-22-2027
  4. Manufactured by Granules Pharmaceuticals Inc.

Where to find product info

FDA recall page D-0670-2025 and manufacturer communications

What timeline to expect

Remedies and refunds typically processed within several weeks to a few months depending on manufacturer policy

If the manufacturer is unresponsive

  • Escalate to FDA recall contacts
  • File complaint with FDA if no response from the manufacturer
  • Consult healthcare provider for alternatives and referrals

How to prevent similar issues

  • Verify supplier recalls before dispensing
  • Track lot-level recalls in pharmacy inventory systems
  • Educate patients about checking bottle labels for lot numbers in future purchases

Documentation advice

Keep recall notices, bottle labels, and communications with the manufacturer; document any adverse events.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Brand: Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate. Manufacturer: Granules Pharmaceuticals Inc., Chantilly, VA 20151. NDC: 70010-030-01. Quantity: 11,895 bottles. Sold nationwide in the USA. Date codes/lot: lot#: GPC250159A. Expiration: 06-22-2027. Reminder: Rx only.

Reported Incidents

No specific injuries or adverse events are reported in the available notice.

Key Facts

  • Lot#: GPC250159A
  • High hazard level
  • Active recall as of 2025-10-01

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPREGNANTPETS
Injury Types
OTHER

Product Classification

Product TypeExtended-Release Capsules (Mixed Salts of a Single Entity Amphetamine Product)
Sold At
Unknown

Product Details

Model Numbers
lot#: GPC250159A
Exp Date: 06-22-2027
UPC Codes
70010-029
70010-030
70010-031
+9 more
Affected States
ALL
Report Date
October 1, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more